Table 3 Time to event analysis during the OLE up to and including Week 128 (SAF-OLE population)
Event, patients with recorded event (n), median days (range) | Patients who started rhPTX-2 (n = 37) | Patients who continued rhPTX-2 (n = 74) | Total (n = 111) |
|---|---|---|---|
Time to first respiratory decline event | n = 9 | n = 39 | n = 48 |
372.0 (47.0–808.0) | 374.0 (5.0–832.0) | 373.0 (5.0–832.0) | |
Time to first exacerbation of IPF | n = 1 | n = 7 | n = 8 |
423.0 (423.0–423.0) | 397.0 (5.0–740.0) | 410.0 (5.0–740.0) | |
Time to first AE of cough | n = 17 | n = 28 | n = 45 |
303.0 (56.0–823.0) | 140.5 (1.0–786.0) | 205.0 (1.0–823.0) | |
Time to lung transplantation | n = 1 | n = 2 | n = 3 |
326.0 (326.0–326.0) | 485.5 (225.0–746.0) | 326.0 (225.0–746.0) | |
Time to discontinuation of study drug | n = 17 | n = 35 | n = 52 |
478.0 (201.0–810.0) | 506.0 (199.0–841.0) | 479.0 (199.0–841.0) | |
Time to death | n = 4 | n = 10 | n = 14 |
525.5 (206.0–858.0) | 488.5 (342.0–784.0) | 488.5 (206.0–858.0) |